SCLX on Nasdaq
Scilex Holding Co
We are an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain.3 From its latest annual report
Price unavailable
Last updated Oct 19, 2026.
Overview
Compare with Scholar Rock Holding Corp, Precision BioSciences or X4 Pharmaceuticals, Inc, or pick any stock.
- TickerSCLX on Nasdaq1
- IndustryBiological Products, (No Diagnostic Substances)1
- HeadquartersPalo Alto, California1
- Incorporated inDE2
- Business address960 San Antonio Road, Palo Alto, Ca 943032
- Filer category, Emerging growth company2
- Legal formCorporation
See how the biggest companies compare on our leaderboards
We are an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. We target indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes.3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
415.8%Gross margin4
-1143.7%Operating margin4
-1236.4%Net margin4
-46.5%Revenue growth, 20254
$3.7MFree cash flow4
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue4¢$10.6M
- Research and development7¢$20.7M
- Selling, general and admin89¢$266.9M
- Income tax0¢$26.0K
Out of $30.3M in revenue.4 The company lost money this year.
Where each dollar of operating cash went, fiscal 2025
- Capital spending3¢$133.0K
- Kept or used elsewhere97¢$3.7M
Out of $3.8M of cash from operations.4
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net Revenue | $30.3M | $56.6M |
| Cost of revenue | $10.6M | $16.7M |
| Research and development | $20.7M | $9.6M |
| Selling, general and administrative | $266.9M | $119.0M |
| Goodwill impairment | $73.4M | $0 |
| Intangible amortization | $4.4M | $4.0M |
| Legal settlements | $345.0K | -$9.4M |
| Total net operating costs and expenses | $376.3M | $140.0M |
| Loss from operations | -$346.0M | -$83.4M |
| (Gain) loss on derivative liability | $22.7M | -$17.4M |
| Change in fair value of debt and liability instruments | $25.4M | $4.8M |
| Interest expense, net | $11.5M | $2.0M |
| Loss on foreign currency exchange | -$86.0K | $45.0K |
| Unrealized loss on digital assets, net | $12.2M | $0 |
| Loss on debt extinguishment, net | $7.4M | $0 |
| Realized loss on digital assets, net | $30.2M | $0 |
| Unrealized (gain) on equity investment, net | -$2.7M | $0 |
| Realized (gain) on equity investments, net | -$19.2M | $0 |
| Unrealized (gain) on equity method investments carried at fair value, net | -$54.8M | $0 |
| Realized (gain) on equity method investments carried at fair value, net | -$4.7M | $0 |
| Realized (gain) on securities | $199.0K | $0 |
| Total other (income) expense, net | $28.0M | -$10.6M |
| Loss before income taxes | -$374.0M | -$72.8M |
| Income tax expense (benefit) | $26.0K | -$1.0K |
| Net loss | -$374.1M | -$72.8M |
| Net Loss Attributable to Common Stockholders Before Deemed Dividend | -$358.7M | -$72.8M |
| Deemed dividend | -$43.8M | $0 |
| Net loss attributable to noncontrolling interests | -$15.3M | $0 |
| Net Income (Loss) Available to Common Stockholders, Basic, Total | -$402.5M | -$72.8M |
| Net comprehensive loss attributable to common stockholders | -$358.7M | -$72.8M |
| Net loss per share attributable to common stockholders - basic | -$36.48 | -$7.24 |
| Net loss per share attributable to common stockholders - diluted | -$36.48 | -$8.05 |
| Weighted average number of shares during the period-basic | 11.0K shares | 10.1K shares |
| Weighted average number of shares, diluted | 11.0K shares | 10.1K shares |
| Foreign currency translation adjustment | -$756.0K | $0 |
| Changes in fair value attributable to instrument-specific credit risk | -$11.4M | $6.3M |
| Total other comprehensive income | -$12.1M | $6.3M |
| Comprehensive loss attributable to common stockholders | -$370.9M | -$66.5M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 5 fiscal years (annual) or 5 quarters (quarterly), latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2024-06-30 | 2024-05-31 | 2023-12-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | $5.0M | $3.3M | |||
| Marketable securities | $6.0M | $0 | |||
| Accounts receivable, net | $15.2M | $26.4M | |||
| Inventory | $4.8M | $2.4M | |||
| Prepaid expenses and other current assets | $7.3M | $9.4M | |||
| Total current assets | $38.4M | $41.5M | |||
| Property and equipment, net | $13.6M | $708.0K | |||
| Operating lease right-of-use asset | $14.8M | $2.2M | |||
| Intangibles, net | $59.1M | $32.5M | |||
| Investments | $1.0M | $2.4M | |||
| Equity method investment, at fair value | $127.0M | $0 | |||
| Digital assets | $64.7M | $0 | |||
| Goodwill | $13.5M | $13.5M | |||
| Other long-term assets | $523.0K | $119.0K | |||
| Total assets | $365.0M | $93.0M | |||
| Accounts payable | $86.3M | $52.6M | |||
| Accrued payroll | $3.3M | $1.5M | |||
| Accrued rebates and fees | $231.8M | $162.5M | |||
| Accrued expenses | $66.4M | $2.8M | |||
| Current portion of deferred consideration | $407.0K | $447.0K | |||
| Debt, current | $83.3M | $34.9M | |||
| Promissory notes | $3.5M | $0 | |||
| Purchased revenue liability, current | $3.8M | $4.1M | |||
| Current portion of operating lease liabilities | $1.7M | $714.0K | |||
| Other current liabilities | $3.3M | $0 | |||
| Total current liabilities | $483.7M | $259.6M | |||
| Long-term portion of deferred consideration | $2.0M | $2.4M | |||
| Debt, net of issuance costs | $22.5M | $845.0K | |||
| Purchased revenue liability, net of current portion | $4.6M | $2.7M | |||
| Derivative liabilities | $50.6M | $18.3M | |||
| Operating lease liabilities, net of current portion | $13.2M | $1.5M | |||
| Other long-term liabilities | $174.0K | $155.0K | |||
| Total liabilities | $576.7M | $285.6M | |||
| Common stock, $0.0001 par value, 740,000,000 shares authorized; 8,491,267 shares issued and 7,033,004 shares outstanding as of December 31, 2025; 6,951,622 shares issued and 5,235,377 shares outstanding as of December 31, 2024 | $1.0K | $1.0K | |||
| Additional paid-in capital | $796.7M | $454.6M | |||
| Accumulated other comprehensive income | -$5.8M | $6.3M | |||
| Accumulated deficit | -$921.8M | -$563.1M | |||
| Treasury stock, at cost; 1,458,263 shares as of December 31, 2025 and 1,716,245 as of December 31, 2024 | -$76.9M | -$90.5M | |||
| Total stockholders' deficit before noncontrolling interests | -$207.8M | -$192.6M | |||
| Noncontrolling interests | -$4.0M | $0 | |||
| Total stockholders' deficit | -$211.8M | -$192.6M | -$172.9M | ||
| Total liabilities and stockholders' deficit | $365.0M | $93.0M | |||
| Preferred Stock, par value | $0.00 | $0.00 | |||
| Preferred stock, shares authorized | 45.0M shares | 45.0M shares | |||
| Common stock, par value | $0.00 | $0.00 | |||
| Common stock, shares authorized | 740.0M shares | 740.0M shares | |||
| Common stock, shares issued | 8.5M shares | 7.0M shares | 3.2M shares | 3.2M shares | |
| Common stock, shares outstanding | 7.0M shares | 5.2M shares | |||
| Treasury stock shares | 1.5M shares | 1.7M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2024-06-30 | 2024-05-31 | 2023-12-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | $5.0M | $3.3M | |||
| Marketable securities | $6.0M | $0 | |||
| Accounts receivable, net | $15.2M | $26.4M | |||
| Inventory | $4.8M | $2.4M | |||
| Prepaid expenses and other current assets | $7.3M | $9.4M | |||
| Total current assets | $38.4M | $41.5M | |||
| Property and equipment, net | $13.6M | $708.0K | |||
| Operating lease right-of-use asset | $14.8M | $2.2M | |||
| Intangibles, net | $59.1M | $32.5M | |||
| Investments | $1.0M | $2.4M | |||
| Equity method investment, at fair value | $127.0M | $0 | |||
| Digital assets | $64.7M | $0 | |||
| Goodwill | $13.5M | $13.5M | |||
| Other long-term assets | $523.0K | $119.0K | |||
| Total assets | $365.0M | $93.0M | |||
| Accounts payable | $86.3M | $52.6M | |||
| Accrued payroll | $3.3M | $1.5M | |||
| Accrued rebates and fees | $231.8M | $162.5M | |||
| Accrued expenses | $66.4M | $2.8M | |||
| Current portion of deferred consideration | $407.0K | $447.0K | |||
| Debt, current | $83.3M | $34.9M | |||
| Promissory notes | $3.5M | $0 | |||
| Purchased revenue liability, current | $3.8M | $4.1M | |||
| Current portion of operating lease liabilities | $1.7M | $714.0K | |||
| Other current liabilities | $3.3M | $0 | |||
| Total current liabilities | $483.7M | $259.6M | |||
| Long-term portion of deferred consideration | $2.0M | $2.4M | |||
| Debt, net of issuance costs | $22.5M | $845.0K | |||
| Purchased revenue liability, net of current portion | $4.6M | $2.7M | |||
| Derivative liabilities | $50.6M | $18.3M | |||
| Operating lease liabilities, net of current portion | $13.2M | $1.5M | |||
| Other long-term liabilities | $174.0K | $155.0K | |||
| Total liabilities | $576.7M | $285.6M | |||
| Common stock, $0.0001 par value, 740,000,000 shares authorized; 8,491,267 shares issued and 7,033,004 shares outstanding as of December 31, 2025; 6,951,622 shares issued and 5,235,377 shares outstanding as of December 31, 2024 | $1.0K | $1.0K | |||
| Additional paid-in capital | $796.7M | $454.6M | |||
| Accumulated other comprehensive income | -$5.8M | $6.3M | |||
| Accumulated deficit | -$921.8M | -$563.1M | |||
| Treasury stock, at cost; 1,458,263 shares as of December 31, 2025 and 1,716,245 as of December 31, 2024 | -$76.9M | -$90.5M | |||
| Total stockholders' deficit before noncontrolling interests | -$207.8M | -$192.6M | |||
| Noncontrolling interests | -$4.0M | $0 | |||
| Total stockholders' deficit | -$211.8M | -$192.6M | -$172.9M | ||
| Total liabilities and stockholders' deficit | $365.0M | $93.0M | |||
| Preferred Stock, par value | $0.00 | $0.00 | |||
| Preferred stock, shares authorized | 45.0M shares | 45.0M shares | |||
| Common stock, par value | $0.00 | $0.00 | |||
| Common stock, shares authorized | 740.0M shares | 740.0M shares | |||
| Common stock, shares issued | 8.5M shares | 7.0M shares | 3.2M shares | 3.2M shares | |
| Common stock, shares outstanding | 7.0M shares | 5.2M shares | |||
| Treasury stock shares | 1.5M shares | 1.7M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$374.1M | -$72.8M |
| Depreciation and amortization | $4.6M | $4.0M |
| Amortization of debt issuance costs and debt discount | $409.0K | $316.0K |
| Non-cash operating lease cost | $812.0K | $718.0K |
| Stock-based compensation | $15.5M | $15.7M |
| Fair value of Gloperba-Elyxyb RPA liability expensed | $500.0K | $0 |
| Fair value of treasury Stock expensed - Tranche B and Oramed Note | $3.6M | $0 |
| Fair value of September 2025 warrants expensed - Tranche B modification | $3.1M | $0 |
| (Gain) loss on derivative liability | $22.7M | -$17.4M |
| Loss on debt extinguishment, net | $7.3M | $0 |
| Goodwill impairment | $73.4M | $0 |
| Financing costs and allocated expense for financial instruments at fair value | $0 | $17.3M |
| In-process research and development expense | $5.4M | $0 |
| Transaction costs expensed related to Semnur Business Combination | $140.0M | $0 |
| Change in fair value of debt and liability instruments | $25.4M | $4.8M |
| Change in fair value of equity investments | -$2.7M | $0 |
| Change in fair value of digital assets | $12.2M | $0 |
| Change in fair value of equity method investment, net | -$54.8M | $0 |
| Realized (gain) loss on investment, net | -$19.2M | $0 |
| Realized (gain) loss on digital assets, net | $30.2M | $0 |
| Realized (gain) loss on equity method investment, net | -$4.7M | $0 |
| Realized Gains & Losses on Securities | $199.0K | $0 |
| Allowances for expected credit losses | $0 | $1.2M |
| Other | -$13.0K | $661.0K |
| Accounts receivables, net | $13.8M | -$6.3M |
| Inventory | $1.8M | $1.5M |
| Prepaid expenses and other | $3.3M | -$479.0K |
| Other long-term assets | -$3.0K | -$30.0K |
| Accounts payable | $13.1M | $7.4M |
| Accrued Payroll | -$1.1M | -$1.2M |
| Accrued expenses | $14.6M | -$8.2M |
| Accrued rebates and fees | $69.2M | $72.9M |
| Operating lease liability | -$857.0K | -$758.0K |
| Other long-term liabilities | $25.0K | -$24.0K |
| Net cash (used for) proceeds from operating activities | $3.8M | $19.3M |
| Acquisition consideration paid in cash for Romeg intangible asset acquisition | -$600.0K | -$600.0K |
| Purchase of equity securities | $0 | -$2.0M |
| Cash paid for in-process research and development, net | -$200.0K | -$75.0K |
| Cash paid to settle Datavault Obligation | -$9.2M | $0 |
| Purchases of Bitcoin with cash | -$15.8M | $0 |
| Purchase of property, plant, and equipment | -$133.0K | $0 |
| Exercise of prefunded warrant | -$27.0K | $0 |
| Purchase of preferred shares of Vivasor | -$9.0M | $0 |
| Sale of Datavault AI Inc. shares for cash, net | $39.6M | $0 |
| Repayments on promissory note | -$962.0K | $0 |
| Payment made for PA OPS investment | -$1.0M | $0 |
| Vivasor Cash Acquired | $1.5M | $0 |
| Purchase of convertible promissory note from Denali | -$50.0K | $0 |
| Net cash used for investing activities | $4.1M | -$2.7M |
| Proceeds from issuance of shares under Standby Equity Purchase Agreements and ATM Sales Agreement | $0 | $2.7M |
| Proceeds from issuance of Revolving Facility | $0 | $95.4M |
| Proceeds from issuance of FSF Deposit | $0 | $10.0M |
| Proceeds from issuance of Tranche B Notes and purchased revenue liability | $0 | $25.0M |
| Repayment of Revolving Facility | $0 | -$112.8M |
| Repayment of Oramed Note | $0 | -$64.2M |
| Cash consideration paid in connection with warrant repurchase | $0 | -$300.0K |
| Cash assumed in Semnur Business Combination | $35.0K | $0 |
| Repayment of Convertible Debentures | $0 | -$4.4M |
| Repayment of Tranche B Notes | -$20.5M | -$3.3M |
| Payments of debt issuance costs | -$71.0K | -$4.2M |
| Cash consideration paid in connection with the repurchase of Penny Warrants | -$27.0M | $0 |
| Payments on purchased revenue liability | -$3.2M | $0 |
| Transaction costs paid in connection with share repurchase | -$996.0K | $0 |
| Proceeds from exercise of April 2024 RDO Warrants and December 2024 RDO Warrants | $20.4M | $0 |
| Transaction costs paid in connection with issuance of common stock and exchange of April 2024 RDO Warrants and December 2024 RDO Warrants for November 2025 Warrants | -$1.7M | $0 |
| Payments for the termination of Tumim Purchase Agreement | -$2.7M | $0 |
| Proceeds from issuance of Scilex-St. James Loans | $21.5M | $0 |
| Excise tax paid in connection with share repurchase | -$860.0K | -$450.0K |
| Proceeds from issuance of shares under direct offerings | $0 | $42.0M |
| Payments of direct offering issuance costs | $0 | -$4.4M |
| Payments of deferred transaction costs related to Semnur Merger | $0 | -$1.4M |
| Proceeds from exercise of December 2024 RDO Warrants for Common Stock | $10.2M | $0 |
| Proceeds from stock options and warrants exercised and ESPP | $23.0K | $2.1M |
| Payments for Vivasor debt | -$558.0K | $0 |
| Payments in lieu of fractional shares for Reverse Stock Split | -$1.0K | $0 |
| Net cash (used for) financing activities | -$5.5M | -$18.1M |
| Effect of exchange rate changes on cash | -$756.0K | $0 |
| Net change in cash and cash equivalents | $1.7M | -$1.5M |
| Cash paid for interest | $935.0K | $1.6M |
| Issuance costs related to direct offerings included in accrued expenses and account payables | $0 | $1.8M |
| Net liabilities assumed in Semnur Business Combination | $12.8M | $0 |
| Derecognition of Scilex's equity investment in Denali in connection with Semnur Business Combination | $2.5M | $0 |
| Exercise of December 2024 RDO Warrants in exchange for settlement of Tranche B Notes principal and interest | $2.7M | $0 |
| Purchase of equity investment in Datavault AI Inc in exchange for Bitcoin | $8.1M | $0 |
| Bitcoin acquired in exchange for shares of Semnur Stock | $200.0M | $0 |
| Additions to intangible assets included in accrued expenses | $1.0M | $0 |
| Fee Warrants issued and exercised in connection with the Commitment Letter | $0 | $610.0K |
| Settlement of FSF Deposit | $0 | $13.0M |
| Deferred transaction costs related to Semnur Merger included in accrued expenses and account payable | $0 | $4.6M |
| Conversion of Oramed Note into Tranche B Notes | $0 | $25.0M |
| Conversion of Tranche B Notes into common stock | $0 | $9.3M |
| Debt issuance costs included in accrued expenses | $0 | $3.1M |
| Placement Agent Shares and October 2024 Placement Agent Warrants | $0 | $3.8M |
| StockBlock Warrants issued in connection with the December 2024 RDO | $0 | $1.3M |
| Datavault Licenses acquired but not yet paid | $30.0M | $0 |
| Purchase of Bitcoin in exchange for Scilex-St. James Loans | $9.4M | $0 |
| Excise tax in connection with share repurchase included in accrued expenses | $0 | $860.0K |
| Purchase and exercise of prefunded warrant for Datavault shares in exchange for Bitcoin | $110.0M | $0 |
| Issuance of warrants as financing costs in connection with issuance of common stock and exchange of liability classified instruments | $862.0K | $0 |
| Vivasor debt forgiveness | -$2.5M | $0 |
| Vivasor net assets consolidated | $0 | $0 |
| Net impact of the issuance of November 2025 Warrants and exchange of liability classified instruments | $6.2M | $0 |
No quarter-by-quarter statement was filed.
Leadership
Who has led Scilex Holding Co, and when. Pick a name to see everywhere that person has worked.
- Chief executive officerHenry Ji Oct 9, 2025 to now11
- ChairHenry Ji Nov 15, 2022 to now12
- PresidentHenry Ji Oct 9, 2025 to now11
Board members and other officers (17)
- OfficerElizabeth Czerepak Nov 15, 2022 to Jan 17, 202313
- OfficerChris Ho Jan 6, 2021 to Jan 6, 202114
- OfficerJeffrey Chi Jan 6, 2021 to Jan 6, 202114
- Board memberHenry Ji Oct 9, 2025 to now11
- Board memberAnnu Navani Aug 12, 2024 to Aug 19, 202415
- Board memberJay Chun Sep 25, 2023 to now16
- Board memberYue Alexander Wu Sep 25, 2023 to now17
- Board memberDavid Lemus Nov 15, 2022 to Oct 18, 202418
- Board memberDorman Followwill Nov 15, 2022 to now19
- Board memberLaura Hamill Nov 15, 2022 to Jan 17, 202320
- Board memberTien-Li Lee Nov 15, 2022 to Jan 17, 202321
- Board memberTommy Thompson Nov 15, 2022 to Jan 17, 202322
- Board memberChris Ho Jan 6, 2021 to Jan 6, 202114
- Board memberJeffrey Chi Jan 6, 2021 to Jan 6, 202114
- Board memberPei Wei Woo Jan 6, 2021 to Jan 6, 202123
- Board memberSteve Myint Jan 6, 2021 to Jan 6, 202124
- Board memberSuneel G. Kaji Jan 6, 2021 to Jan 6, 202125
Named in SEC Form D filings
People the company listed in its private-offering notices.
Former names
Timeline
- Oct 9, 2025New chief executive Henry Ji becomes CEO11
Filings
703 filings to the SEC since October 2021: 6 annual reports, 16 quarterly reports, 144 major events, 80 insider forms, 33 large holders, 2 private raises, 422 other. The latest 20:
- Sep 29, 20268-K EDGAR
- Aug 24, 2026SCHEDULE 13D/A EDGAR
- Aug 14, 202610-Q EDGAR
- Aug 12, 20268-K EDGAR
- Jul 22, 20268-K EDGAR
- Jul 7, 2026SCHEDULE 13D/A EDGAR
- Jul 7, 20264 EDGAR
- Jul 6, 20268-K EDGAR
- Jun 30, 2026S-8 EDGAR
- Jun 29, 20268-K EDGAR
- Jun 24, 20268-K EDGAR
- Jun 11, 2026EFFECT EDGAR
- Jun 9, 2026CORRESP EDGAR
- Jun 9, 2026UPLOAD EDGAR
- Jun 2, 2026S-3 EDGAR
- May 22, 2026EFFECT EDGAR
- May 20, 2026CORRESP EDGAR
- May 20, 202610-Q EDGAR
- May 15, 2026NT 10-Q EDGAR
- May 11, 20268-K EDGAR
The 703 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
19 open-market trades by officers, directors and large owners since October 2021: 15 buys and 4 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Dec 30, 2025 | Scilex Holding Co10% owner | Sale | 9,657,300 | $0.54 | $5.2M | Form 4 |
| Dec 29, 2025 | Scilex Holding Co10% owner | Sale | 7,310,984 | $0.66 | $4.8M | Form 4 |
| Dec 26, 2025 | Scilex Holding Co10% owner | Sale | 3,689,016 | $0.75 | $2.8M | Form 4 |
| Dec 18, 2024 | SHAH JAISIMSee Remarks | Buy | 30,000 | $0.46 | $13.8K | Form 4 |
| Oct 31, 2024 | Ji HenryExec Chair, CEO and President | Buy | 8,888 | $0.94 | $8.4K | Form 4 |
| Oct 29, 2024 | SHAH JAISIMSee Remarks | Buy | 32,000 | $0.99 | $31.7K | Form 4 |
| Oct 18, 2024 | Followwill DormanDirector | Buy | 1,000 | $0.99 | $990 | Form 4 |
| Oct 18, 2024 | Chun JayDirector | Buy | 5,000 | $0.95 | $4.8K | Form 4 |
| Oct 17, 2024 | Wu Yue AlexanderDirector | Buy | 20,000 | $0.95 | $19.0K | Form 4 |
| Oct 17, 2024 | Lemus DavidDirector | Buy | 2,000 | $0.90 | $1.8K | Form 4 |
| Oct 17, 2024 | Ji HenryExec Chair, CEO and President | Buy | 10,000 | $0.97 | $9.7K | Form 4 |
| Oct 16, 2024 | SHAH JAISIMSee Remarks | Buy | 30,000 | $0.99 | $29.7K | Form 4 |
| Oct 16, 2024 | Ma Stephen HoiCFO, COO and Secretary | Buy | 6,700 | $0.97 | $6.5K | Form 4 |
| May 17, 2024 | Ji HenryExec Chair, CEO and President | Buy | 50,000 | $0.88 | $44.0K | Form 4 |
| May 17, 2024 | Chun JayDirector | Buy | 57,500 | $0.90 | $51.8K | Form 4 |
| May 17, 2024 | SHAH JAISIMSee Remarks | Buy | 56,939 | $0.92 | $52.4K | Form 4 |
| May 17, 2024 | Ma Stephen HoiCFO, COO and Secretary | Buy | 14,140 | $0.88 | $12.4K | Form 4 |
| May 16, 2024 | SHAH JAISIMSee Remarks | Buy | 83,061 | $0.84 | $69.8K | Form 4 |
| Sep 21, 2023 | Sorrento Therapeutics, Inc.10% owner | Sale | 60,068,585 | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- SCLX Stock Acquisition JV LLCSCHEDULE 13D/A, 7 filings Sep 29, 2023 to Jul 7, 202628
- Semnur, Inc.SCHEDULE 13D, 1 filing Sep 26, 202529
- Hudson Bay Capital Management LPSC 13G/A, 2 filings Feb 3, 2022 to Feb 13, 202330
- Karpus Management, Inc.SC 13G/A, 2 filings Jan 10, 2022 to Dec 9, 202231
- Lawrence FeisSC 13G/A, 2 filings Jul 27, 2022 to Nov 14, 202232
- CVI Investments, Inc.SC 13G/A, 1 filing Feb 14, 202233
- Shaolin Capital Management LLCSC 13G, 1 filing Feb 11, 202234
- Space Summit Capital LLCSC 13G/A, 1 filing Feb 2, 202235
Money raised
Private offerings the company reported to the SEC on Form D.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 70. Change is in shares since the quarter before.
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11SEC EDGARHenry Ji, Chief executive officer
- 12SEC EDGARHenry Ji, Chair
- 13SEC EDGARElizabeth Czerepak, Officer
- 14SEC EDGARChris Ho, Officer
- 15SEC EDGARAnnu Navani, Board member
- 16SEC EDGARJay Chun, Board member
- 17SEC EDGARYue Alexander Wu, Board member
- 18SEC EDGARDavid Lemus, Board member
- 19SEC EDGARDorman Followwill, Board member
- 20SEC EDGARLaura Hamill, Board member
- 21SEC EDGARTien-Li Lee, Board member
- 22SEC EDGARTommy Thompson, Board member
- 23SEC EDGARPei Wei Woo, Board member
- 24SEC EDGARSteve Myint, Board member
- 25SEC EDGARSuneel G. Kaji, Board member
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35